共 228 条
[1]
Hightower KE(2011)Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes Antimicrob Agents Chemother 55 4552-4559
[2]
Wang R(2012)The development of novel HIV integrase inhibitors and the problem of drug resistance Current Opinion in Virology 2656 662-100
[3]
DeAnda F(2013)HIV drug resistance and the advent of integrase inhibitors Curr Infect Dis Rep 15 85-1986
[4]
Johns BA(1994)Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases Science 266 1981-23216
[5]
Weaver K(2001)HIV integrase, a brief overview from chemistry to therapeutics J Biol Chem 276 23213-806
[6]
Shen Y(2009)Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial Lancet 374 796-48
[7]
Tomberlin GH(2010)Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses JAIDS Journal of Acquired Immune Deficiency Syndromes 55 39-2448
[8]
Carter HL(2012)Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks Lancet 379 2439-100
[9]
Broderick T(2013)A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results JAIDS Journal of Acquired Immune Deficiency Syndromes 63 96-118
[10]
Sigethy S(2012)Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial The Lancet infectious diseases 12 111-47